Pfizer Share Price
Sector: Major Drugs
You have to be logged in to add this to Watchlist.
Login or Register
5787.05 +92.60 (1.63%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
5748
Today’s High
5925
52 Week Low
3834.4
52 Week High
6452.85
5795.00 +106.05 (1.86%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
5729.95
Today’s High
5929
52 Week Low
3838
52 Week High
6451.15
Key Metrics
- Market Cap (In Cr) 26025.66
- Beta 0.41
- Div. Yield (%) 0.62
- P/B 7.24
- TTM P/E 34.05
- Peg Ratio 6.97
- Sector P/E 32.9
- D/E -
- Open Price 5748
- Prev Close 5694.45
Pfizer Analysis
Price Analysis
-
1 Week-0.3%
-
3 Months13.67%
-
6 Month38.27%
-
YTD33.26%
-
1 Year43.4%
Risk Meter
- 28% Low risk
- 28% Moderate risk
- 28% Balanced Risk
- 28% High risk
- 28% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 1
- 1
- 1
- 2
- Buy
- 0
- 0
- 0
- 0
- Hold
- 2
- 2
- 2
- 1
- Sell
- 0
- 0
- 0
- 0
- Strong Sell
- 0
- 0
- 0
- 0
- Total
- 3
- 3
- 3
- 3
Pfizer News
Stocks to Watch: Tata Motors, Nykaa, Ola Electric, Hi-Tech Pipes, and more
3 min read . 08 Oct 2024Pfizer Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 2193.17
- Selling/ General/ Admin Expenses Total
- 347.8
- Depreciation/ Amortization
- 62.28
- Other Operating Expenses Total
- 417.5
- Total Operating Expense
- 1612.2
- Operating Income
- 580.97
- Net Income Before Taxes
- 746.07
- Net Income
- 551.33
- Diluted Normalized EPS
- 117.95
- Period
- 2024
- Total Assets
- 4228.78
- Total Liabilities
- 633.24
- Total Equity
- 3595.54
- Tangible Book Valueper Share Common Eq
- 663.15
- Period
- 2024
- Cashfrom Operating Activities
- 256.84
- Cashfrom Investing Activities
- 53.7
- Cashfrom Financing Activities
- -235.14
- Net Changein Cash
- 75.4
- Period
- 2023
- Total Revenue
- 2424.76
- Selling/ General/ Admin Expenses Total
- 650.55
- Depreciation/ Amortization
- 104.02
- Other Operating Expenses Total
- 30.07
- Total Operating Expense
- 1680.32
- Operating Income
- 744.44
- Net Income Before Taxes
- 824.01
- Net Income
- 623.93
- Diluted Normalized EPS
- 130.83
- Period
- 2023
- Total Assets
- 4000.73
- Total Liabilities
- 793.43
- Total Equity
- 3207.3
- Tangible Book Valueper Share Common Eq
- 576.11
- Period
- 2023
- Cashfrom Operating Activities
- 355.68
- Cashfrom Investing Activities
- -36.05
- Cashfrom Financing Activities
- -345.79
- Net Changein Cash
- -26.16
- Period
- 2022
- Total Revenue
- 2610.99
- Selling/ General/ Admin Expenses Total
- 740.31
- Depreciation/ Amortization
- 113.61
- Other Operating Expenses Total
- 18.38
- Total Operating Expense
- 1879.37
- Operating Income
- 731.62
- Net Income Before Taxes
- 772.89
- Net Income
- 612.56
- Diluted Normalized EPS
- 133.1
- Period
- 2022
- Total Assets
- 3900.51
- Total Liabilities
- 1036.1
- Total Equity
- 2864.41
- Tangible Book Valueper Share Common Eq
- 490.16
- Period
- 2022
- Cashfrom Operating Activities
- 667.08
- Cashfrom Investing Activities
- -575.02
- Cashfrom Financing Activities
- -180.51
- Net Changein Cash
- -88.45
- Period
- 2021
- Total Revenue
- 2238.55
- Selling/ General/ Admin Expenses Total
- 633.05
- Depreciation/ Amortization
- 108.02
- Other Operating Expenses Total
- 28.26
- Total Operating Expense
- 1625.23
- Operating Income
- 613.32
- Net Income Before Taxes
- 668.72
- Net Income
- 497.61
- Diluted Normalized EPS
- 108.07
- Period
- 2021
- Total Assets
- 3265.9
- Total Liabilities
- 872.86
- Total Equity
- 2393.04
- Tangible Book Valueper Share Common Eq
- 376.12
- Period
- 2021
- Cashfrom Operating Activities
- 427.33
- Cashfrom Investing Activities
- -468.84
- Cashfrom Financing Activities
- -1571.07
- Net Changein Cash
- -1612.58
- Period
- 2020
- Total Revenue
- 2151.65
- Selling/ General/ Admin Expenses Total
- 692.65
- Depreciation/ Amortization
- 101.86
- Other Operating Expenses Total
- 22.81
- Total Operating Expense
- 1639.57
- Operating Income
- 512.08
- Net Income Before Taxes
- 642.49
- Net Income
- 509.13
- Diluted Normalized EPS
- 106.14
- Period
- 2020
- Total Assets
- 4405.4
- Total Liabilities
- 1009.91
- Total Equity
- 3395.49
- Tangible Book Valueper Share Common Eq
- 583.22
- Period
- 2020
- Cashfrom Operating Activities
- 323.18
- Cashfrom Investing Activities
- 1530.32
- Cashfrom Financing Activities
- -163.52
- Net Changein Cash
- 1689.98
- Period
- 2019
- Total Revenue
- 2081.5
- Selling/ General/ Admin Expenses Total
- 665.24
- Depreciation/ Amortization
- 70
- Other Operating Expenses Total
- 22.59
- Total Operating Expense
- 1546.84
- Operating Income
- 534.66
- Net Income Before Taxes
- 659.91
- Net Income
- 429.05
- Diluted Normalized EPS
- 89.67
- Period
- 2019
- Total Assets
- 3939.99
- Total Liabilities
- 928.65
- Total Equity
- 3011.34
- Tangible Book Valueper Share Common Eq
- 487.19
- Period
- 2019
- Cashfrom Operating Activities
- 97.81
- Cashfrom Investing Activities
- 35.12
- Cashfrom Financing Activities
- -109.85
- Net Changein Cash
- 23.08
- Period
- 2018
- Total Revenue
- 1980.19
- Selling/ General/ Admin Expenses Total
- 638.73
- Depreciation/ Amortization
- 64.86
- Other Operating Expenses Total
- 18.2
- Total Operating Expense
- 1537.03
- Operating Income
- 443.16
- Net Income Before Taxes
- 547.91
- Net Income
- 360.07
- Diluted Normalized EPS
- 78.69
- Period
- 2018
- Total Assets
- 3689.96
- Total Liabilities
- 1006.76
- Total Equity
- 2683.2
- Tangible Book Valueper Share Common Eq
- 403.98
- Period
- 2018
- Cashfrom Operating Activities
- 331.8
- Cashfrom Investing Activities
- -238.3
- Cashfrom Financing Activities
- -110.35
- Net Changein Cash
- -16.85
- Period
- 2024-06-30
- Total Revenue
- 562.86
- Selling/ General/ Admin Expenses Total
- 91.37
- Depreciation/ Amortization
- 14.6
- Other Operating Expenses Total
- 93.31
- Total Operating Expense
- 399.97
- Operating Income
- 162.89
- Net Income Before Taxes
- 202.62
- Net Income
- 150.71
- Diluted Normalized EPS
- 32.94
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 546.63
- Selling/ General/ Admin Expenses Total
- 75.11
- Depreciation/ Amortization
- 13.75
- Other Operating Expenses Total
- 92.75
- Total Operating Expense
- 370.95
- Operating Income
- 175.68
- Net Income Before Taxes
- 243.86
- Net Income
- 178.86
- Diluted Normalized EPS
- 39.1
- Period
- 2024-03-31
- Total Assets
- 4228.78
- Total Liabilities
- 633.24
- Total Equity
- 3595.54
- Tangible Book Valueper Share Common Eq
- 663.15
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 256.84
- Cashfrom Investing Activities
- 53.7
- Cashfrom Financing Activities
- -235.14
- Net Changein Cash
- 75.4
- Period
- 2023-12-31
- Total Revenue
- 539.97
- Selling/ General/ Admin Expenses Total
- 89.37
- Depreciation/ Amortization
- 17.55
- Other Operating Expenses Total
- 115.49
- Total Operating Expense
- 397.02
- Operating Income
- 142.95
- Net Income Before Taxes
- 175.94
- Net Income
- 129.98
- Diluted Normalized EPS
- 27.14
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 575.21
- Selling/ General/ Admin Expenses Total
- 89.8
- Depreciation/ Amortization
- 15.43
- Other Operating Expenses Total
- 98.03
- Total Operating Expense
- 408.03
- Operating Income
- 167.18
- Net Income Before Taxes
- 200.52
- Net Income
- 148.96
- Diluted Normalized EPS
- 32.56
- Period
- 2023-09-30
- Total Assets
- 4006.2
- Total Liabilities
- 733.21
- Total Equity
- 3272.99
- Tangible Book Valueper Share Common Eq
- 591.56
- Period
- 2023-09-30
- Cashfrom Operating Activities
- 189.75
- Cashfrom Investing Activities
- -2.05
- Cashfrom Financing Activities
- -208.52
- Net Changein Cash
- -20.82
- Period
- 2023-06-30
- Total Revenue
- 531.36
- Selling/ General/ Admin Expenses Total
- 93.52
- Depreciation/ Amortization
- 15.55
- Other Operating Expenses Total
- 111.23
- Total Operating Expense
- 436.2
- Operating Income
- 95.16
- Net Income Before Taxes
- 125.75
- Net Income
- 93.53
- Diluted Normalized EPS
- 20.44
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 572.64
- Selling/ General/ Admin Expenses Total
- 65.31
- Depreciation/ Amortization
- 26.41
- Other Operating Expenses Total
- 109.45
- Total Operating Expense
- 436.77
- Operating Income
- 135.87
- Net Income Before Taxes
- 164.72
- Net Income
- 129.65
- Diluted Normalized EPS
- 31.71
- Period
- 2023-03-31
- Total Assets
- 4000.73
- Total Liabilities
- 793.43
- Total Equity
- 3207.3
- Tangible Book Valueper Share Common Eq
- 576.11
- Period
- 2023-03-31
- Cashfrom Operating Activities
- 355.68
- Cashfrom Investing Activities
- -36.05
- Cashfrom Financing Activities
- -345.79
- Net Changein Cash
- -26.16
- Period
- 2022-12-31
- Total Revenue
- 621.75
- Selling/ General/ Admin Expenses Total
- 91.69
- Depreciation/ Amortization
- 26.34
- Other Operating Expenses Total
- 109.41
- Total Operating Expense
- 444.64
- Operating Income
- 177.11
- Net Income Before Taxes
- 200.68
- Net Income
- 150.66
- Diluted Normalized EPS
- 32.93
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Pfizer Technical
Moving Average
SMA
- 5 Day5762.14
- 10 Day5674.06
- 20 Day5667.07
- 50 Day5825.55
- 100 Day5324.74
- 300 Day4835.25
Pfizer Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Aurobindo Pharma
- 1466
- -16.7
- -1.13
- 1592.55
- 834.9
- 85892.94
- Pfizer
- 5787.05
- 92.6
- 1.63
- 6452.85
- 3834.4
- 26474.44
- Neuland Laboratories
- 15352.15
- -956.4
- -5.86
- 16501
- 3612.05
- 19696.64
- Astrazeneca Pharma India
- 7623.15
- -8.25
- -0.11
- 8139.85
- 4050.15
- 19057.88
- Unichem Laboratories
- 725.9
- -2.6
- -0.36
- 755.15
- 398.7
- 5110.75
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Aurobindo Pharma
- 25.97
- 2.91
- 14.22
- 12.72
- Pfizer
- 48.15
- 7.33
- 18.43
- 24.05
- Neuland Laboratories
- 63.05
- 15.65
- 14.98
- 11.99
- Astrazeneca Pharma India
- 126.67
- 26.74
- 20.1
- 10.27
- Unichem Laboratories
- -
- 2.22
- -2.1
- -3.99
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 29-Jul-24
- Quarterly Results
- 17-May-24
- Audited Results & Final Dividend
- 09-Feb-24
- Quarterly Results
- 28-Oct-23
- Quarterly Results
- 11-Aug-23
- Quarterly Results
- 15-May-23
- Audited Results & Final Dividend
- 09-Feb-23
- Quarterly Results
- 11-Nov-22
- Quarterly Results
- 05-Aug-22
- Quarterly Results
- 20-May-22
- Audited Results & Dividend
- Meeting Date
- Announced on
- Purpose
- 02-Apr-24
- 29-Feb-24
- POM
- 09-Jan-24
- 07-Dec-23
- POM
- 18-Aug-23
- 15-May-23
- AGM
- 26-Aug-22
- 20-May-22
- AGM
- 19-Aug-21
- 28-Jul-21
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 17-May-24
- 21-Aug-24
- 21-Aug-24
- 35
- 15-May-23
- 11-Aug-23
- 11-Aug-23
- 35
- 16-May-23
- 11-Aug-23
- 11-Aug-23
- 5
- 06-Sept-22
- 20-Sept-22
- 19-Sept-22
- 30
- 27-May-21
- -
- 11-Aug-21
- 5
- 26-May-21
- -
- 11-Aug-21
- 30